Aditxt, Inc. Proceeds from License Fees Received
Aditxt, Inc. (ADTX) reported Proceeds from License Fees Received of $44.59 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLicenseFeesReceived · last filed 2026-05-20
- Aditxt, Inc. proceeds from license fees received for the quarter ending 2026-03-31 was $44.59K, a 55.99% decline year-over-year.
- Aditxt, Inc. proceeds from license fees received for the quarter ending 2025-12-31 was $9.66K.
- Aditxt, Inc. proceeds from license fees received for the quarter ending 2025-09-30 was $1.63K, a 559.11% increase year-over-year.
- Aditxt, Inc. proceeds from license fees received for the quarter ending 2025-06-30 was $7.18K.
- Aditxt, Inc. proceeds from license fees received for fiscal 2025 was $119.81K, a 93.51% increase from fiscal 2024.
- Aditxt, Inc. proceeds from license fees received for fiscal 2024 was $61.91K, a 49.88% decline from fiscal 2023.
- Aditxt, Inc. proceeds from license fees received for fiscal 2023 was $123.54K.
| Period end | Proceeds from License Fees Received 3 month | Proceeds from License Fees Received 6 month | Proceeds from License Fees Received 9 month | Proceeds from License Fees Received 12 month | Proceeds from License Fees Received 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $44.59K 10-Q · filed 2026-05-20 | $54.26K derived: sum of 2 quarters · filed 2026-05-20 | $55.88K derived: sum of 3 quarters · filed 2026-05-20 | $63.06K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-12-31 | $9.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $11.29K derived: sum of 2 quarters · filed 2026-03-31 | $18.47K derived: sum of 3 quarters · filed 2026-03-31 | $119.81K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $1.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | $8.81K derived: sum of 2 quarters · filed 2025-11-18 | $110.15K 10-Q · filed 2025-11-18 | $110.15K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-06-30 | $7.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $108.52K 10-Q · filed 2025-08-14 | $108.52K derived: sum of 3 quarters · filed 2026-05-20 | $108.77K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-03-31 | $101.34K 10-Q · filed 2026-05-20 | $101.34K derived: sum of 2 quarters · filed 2026-05-20 | $101.59K derived: sum of 3 quarters · filed 2026-05-20 | $101.59K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $247.00 derived: sum of 2 quarters · filed 2026-03-31 | $247.00 derived: sum of 3 quarters · filed 2026-03-31 | $61.91K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $247.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | $247.00 derived: sum of 2 quarters · filed 2025-11-18 | $61.91K 10-Q · filed 2025-11-18 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $61.67K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $61.67K 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | $123.54K 10-K · filed 2025-03-31 | $60.00K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |